Related Experiment Video

Updated: Jun 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity

Thomas Sersté1, Marcel Nkuize, Rami Moucari

  • 1Hépato-Gastroentérologie, Hôpital Saint-Pierre, Université Libre de Bruxelles, Bruxelles, Belgium. thomas.serste@skynet.be

Liver International : Official Journal of the International Association for the Study of the Liver
|June 12, 2010
PubMed

Insights

Hepatitis C virus (HCV) genotypes 1 and 4 are linked to insulin resistance in chronic hepatitis C (CHC) patients. Ethnicity did not show an independent association with metabolic disorders in this CHC cohort.

Area of Science:

  • Hepatology
  • Metabolic Disorders
  • Virology

Background:

  • Hepatitis C virus (HCV) infection is associated with an increased risk of metabolic disorders.
  • Genotypes 1 and 4 of HCV are particularly implicated in this risk.
  • Chronic hepatitis C (CHC) patients require evaluation for metabolic complications.

Purpose of the Study:

  • To investigate the associations between metabolic disorders, ethnicity, and HCV genotype in a large CHC patient cohort.
  • To determine the prevalence of metabolic syndrome and insulin resistance in CHC patients.
  • To identify independent predictors of insulin resistance in CHC.

Main Methods:

  • A cohort of 454 consecutive CHC patients was analyzed.
  • Demographic data and metabolic syndrome variables were collected.
  • Insulin resistance was assessed using the homeostasis model for the assessment of insulin resistance (HOMA-IR) test.

Main Results:

  • The prevalence of metabolic syndrome was 12.4% among CHC patients.
  • Insulin resistance was present in 35.0% of patients tested (n=140).
  • HCV genotypes 1/4 were significantly associated with higher rates of insulin resistance and Black African ethnicity compared to genotypes 2/3. Genotypes 1/4 and older age were independent predictors of insulin resistance.

Conclusions:

  • Insulin resistance in CHC is independently associated with HCV genotypes 1 and 4.
  • Ethnicity was not found to be an independent risk factor for metabolic disorders in this CHC population.
Abstract

More Related Videos

Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model06:21

Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model

Published on: October 6, 2023

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...